Clovis Oncology, Inc. CLVS
Set alert
0.08 0.00 0.00%
At close · Dec 20
0.078 Day range 0.0977
52-week range unavailable
- Open
- 0.0808
- Prev close
- 0.0812
- Mkt cap
- 0
- Vol
- 24.21M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.078
- High
- 0.0977
- Forward P/E
- -0.10
- Beta
- 0.22
- Short ratio
- 4.63
- Inst. own
- 25.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2022
- 50-d avg
- 0.517402
- 200-d avg
- 1.26
- 1y target
- 2.00
3M chart
Events in this range
- Nov 9, 2022Earnings: —; estimate -0.42; surprise —%
- Nov 10, 2022Downgrade: JP Morgan · Neutral → Underweight
Signals (12)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Dec 5, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 28, 2022 | 3 years ago |
| RSI: Oversold | Nov 9, 2022 | 3 years ago |
| MACD: Sell Signal | Oct 31, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 28, 2022 | 4 years ago |
| MACD: Sell Signal | Oct 24, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 17, 2022 | 4 years ago |
| MACD: Sell Signal | Oct 12, 2022 | 4 years ago |
| SMA: Bearish | Oct 7, 2022 | 4 years ago |
| SMA: Bullish | Oct 3, 2022 | 4 years ago |
| MACD: Buy Signal | Sep 29, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 26, 2022 | 4 years ago |
Analyst view
Consensus: hold
Hold
Price target (mean) 2.00
Ratings (0m) 14 10 buy · 4 hold · 0 sell
- Strong buy4
- Buy6
- Hold4
- Sell0
- Strong sell0
Recommendation trend
- This month 14
- 1 month ago 2
- 2 months ago 3
- 3 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.37 | -0.37 – -0.37 | -0.48 | +22.9% | 32.08M | -10.8% | 1 |
| Current year | -1.68 | -1.68 – -1.68 | -2.27 | +26.0% | 130.42M | -12.3% | 1 |
| Next year | -0.83 | -0.83 – -0.83 | -1.68 | +50.6% | 137.38M | +5.3% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2022 | JP Morgan | Downgrade | Neutral | Underweight |
| May 6, 2022 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| May 5, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 21, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Aug 5, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| May 5, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 6, 2020 | SVB Leerink | Maintained | — | Underperform |
| Nov 6, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| May 22, 2020 | HC Wainwright & Co. | Reiterated | — | Buy |
| May 20, 2020 | SVB Leerink | Maintained | — | Underperform |
| May 18, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| May 6, 2020 | H.C. Wainwright | Reiterated | — | Buy |
| Apr 27, 2020 | SVB Leerink | Downgrade | Market Perform | Underperform |
| Apr 9, 2020 | B of A Securities | Downgrade | Neutral | Underperform |
| Jan 23, 2020 | B of A Securities | Maintained | — | Neutral |
| Nov 19, 2019 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| Oct 8, 2019 | Goldman Sachs | Maintained | — | Sell |
| Sep 24, 2019 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Aug 13, 2019 | Bank of America | Downgrade | Buy | Neutral |
| Aug 2, 2019 | Guggenheim | Downgrade | Buy | Neutral |
| May 29, 2019 | Goldman Sachs | Downgrade | Neutral | Sell |
| Feb 13, 2019 | H.C. Wainwright | Initiated | — | Buy |
| Oct 31, 2018 | Barclays | Maintained | Overweight | Overweight |
| Oct 31, 2018 | JP Morgan | Downgrade | Overweight | Neutral |
| Sep 25, 2018 | Leerink Swann | Initiated | — | Market Perform |
| Feb 27, 2018 | Barclays | Maintained | Overweight | Overweight |
| Feb 27, 2018 | Stifel Nicolaus | Maintained | Buy | Buy |
| Feb 22, 2018 | Evercore ISI Group | Upgrade | In-Line | Outperform |
| Feb 22, 2018 | RBC Capital | Upgrade | Sector Perform | Outperform |
| Nov 2, 2017 | Morgan Stanley | Maintained | — | Overweight |